Guidelines for the treatment of localized prostate cancer typically recommend the addition of androgen-deprivation therapy (ADT) to radiation therapy (RT) in certain patients, as it has been shown to improve metastasis-free survival at the population level. Jonathan D. Tward, MD, PhD, and colleagues developed a new mathematical model to determine the benefit of adding ADT to RT as a function of the personalized clinical cell-cycle risk (CCR) score to ascertain 10-year metastasis risk. ...
Localized Prostate Cancer
Advertisement
Latest News
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Trending
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
